PatientsLikeMe and BBK Worldwide Join Forces to Bring Mass Patient Exposure to the Clinical Research Process
PatientsLikeMe
and
BBK Worldwide
announce an alliance to jointly offer their services to pharmaceutical companies and other industry stakeholders interested in enhancing patient recruitment and retention for ongoing and upcoming clinical research studies. Both companies have a long-standing commitment to raising awareness of trials among patients, as recently underscored by PatientsLikeMe’s award from the Institute of Medicine for its new clinical trial feature and by BBK’s research, such as its widely-cited “Will and Why” surveys of global patient attitudes toward participation in clinical studies.
“There’s great synergy in our two companies working together,” says Joan F. Bachenheimer, founder and CEO of BBK Worldwide. “With our clinical trial solutions and PatientsLikeMes patient engagement platform, we’ll be able to create a steady stream of interested and eligible clinical trial participants for clients with the greatest depth of members’ health information in the industry.”
To help expand its targeted patient population for recruitment purposes, the two companies will launch national and regional multi-media campaigns to help drive patients to sign up for PatientsLikeMe, where there are currently 100,000+ patients with more than 500 conditions. While patients will benefit from sharing their health data and experiences on the site, BBK and PatientsLikeMe will offer industry partners tiered access to interested patient members who meet their trial criteria. Trial sponsors also will be able to leverage the PatientsLikeMe platform and the BBK technological solutions and communications expertise to establish powerful retention programs.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.
